Atomo Diagnostics has closed a modest Share Purchase Plan, raising $44,500 and issuing free attaching options, while reserving a substantial shortfall for future placement.
- SPP raised $44,500 from 1.35 million shares
- Shareholders received 674,229 free options
- Issue price set at 3.3 cents per share
- Shortfall of $955,500 remains unplaced
- Funds support operational activities
Modest Capital Raise Completes with Attaching Options
Atomo Diagnostics Limited (ASX:AT1) has wrapped up its latest Share Purchase Plan (SPP), raising a relatively small $44,500 through the issuance of 1,348,480 shares at 3.3 cents each. Eligible shareholders in Australia and New Zealand also received 674,229 free attaching options exercisable at 4.5 cents, valid for 2.5 years. The shares will rank equally with existing stock, reinforcing shareholder value continuity.
Significant Shortfall Reserved for Future Placement
Despite the completion of the SPP, a sizeable shortfall of $955,500 remains unallocated, which the company has reserved the right to place at its discretion. Details on timing and pricing for this placement have not been disclosed, leaving investors to watch closely for how Atomo intends to fill this gap and the potential dilution effects.
Funding Positioned to Support Operational Momentum
Managing Director and CEO John Kelly expressed appreciation for shareholder participation and highlighted that the funds raised, though modest, position Atomo to advance its operational activities. This fundraising effort follows a period of strategic expansion, including the company’s recent growth in the US market driven by the FDA CLIA waiver for Lumos Diagnostics’ FebriDx test, which has significantly boosted demand for Atomo’s Pascal cassette technology FDA CLIA waiver. The current capital raise complements earlier funding rounds, including a $3 million raise earlier this year that strengthened Atomo’s balance sheet and supported international expansion $3 million capital raise.
Patented Devices and Market Position
Atomo’s patented rapid diagnostic test devices continue to underpin its market presence across infectious disease testing and early detection applications. The company’s supply agreements and product commercialisation efforts remain key pillars of its strategy, with the recent capital raise aimed at sustaining this momentum amid evolving market dynamics.
Bottom Line?
The modest SPP raise and attaching options provide some operational runway, but the substantial shortfall leaves questions about timing and impact of further capital raising.
Questions in the middle?
- When and how will Atomo place the $955,500 shortfall?
- What impact will option exercises have on future capital structure?
- How will Atomo balance funding needs with ongoing operational expansion?